What Does LVEF Mean After a Heart Attack? Explained
At a Glance
After a heart attack, LVEF is the percentage of blood the left ventricle pumps with each beat. A lower result can mean weaker pumping, but it may improve as stunned muscle recovers, so doctors interpret it with symptoms and other tests.
In this answer
5 sections
Left ventricular ejection fraction (LVEF) is a measurement, expressed as a percentage, of how much blood the main pumping chamber of your heart (the left ventricle) pushes out to the body with each heartbeat [1]. After an acute myocardial infarction (heart attack), doctors use an ultrasound of the heart (echocardiogram) to measure this number [2]. It helps your care team understand how the heart’s pumping function was affected and guides your medication plan. However, LVEF is just one piece of the puzzle—it is a snapshot of your heart’s pumping mechanics, not a complete measure of your overall health or a definitive predictor of how you will feel day-to-day [3].
When to Seek Immediate Help
Do not wait for an upcoming echocardiogram or doctor’s appointment if you feel worse. Call emergency services (like 911) if you experience:
- New or returning chest pressure, tightness, or pain
- Severe or rapidly worsening shortness of breath
- Fainting or severe dizziness
- A sustained racing or irregular heartbeat
- Sudden confusion, weakness, or a cold sweat
Call your cardiology team promptly if you notice increasing swelling in your legs or rapid weight gain (often a sign of fluid buildup).
Making Sense of the Numbers
Cardiologists generally group LVEF into three main categories to help guide treatment [1]:
- Preserved LVEF (50% or higher): The heart is pumping at a normal or near-normal level. However, a preserved EF does not mean the heart attack caused no damage, and it does not rule out heart disease. It is still possible to experience symptoms like shortness of breath [4]. Keep in mind that 50% can be considered “low-normal” depending on the laboratory, and measurements can vary slightly between different tests and sonographers.
- Mildly reduced LVEF (41% to 49%): The heart’s pumping ability is slightly lower than normal.
- Substantially reduced LVEF (40% or lower): The heart’s pumping ability is significantly decreased. A lower number is generally linked to a higher risk of future cardiac events and usually means you will need specific medications to support the heart’s function [5][6].
Regional Wall-Motion Abnormalities: Interpreting the Scan
A heart attack typically happens when blood flow is blocked or severely reduced in a specific coronary artery, meaning the injury is usually localized rather than affecting the whole heart equally. When a sonographer performs your echocardiogram, they look closely at how different segments of the heart wall are moving.
These localized findings on your scan are called regional wall-motion abnormalities [7]. A specific segment of the heart wall might be described as hypokinetic (moving weakly) or akinetic (not moving at all) [7]. It is important to know that these abnormalities are imaging findings—they suggest which region was affected, but they are not absolute proof of permanent damage. They must be interpreted alongside your clinical history, as they can reflect an old scar, acute lack of blood flow, or temporarily stunned muscle [8].
Stunned Muscle and the Potential for Recovery
It is important to know that your LVEF number measured immediately after a heart attack may not be your permanent baseline.
During a heart attack, some heart muscle cells die and eventually form a permanent scar [9]. However, other areas of the muscle may simply be “stunned” by the temporary lack of blood flow and oxygen [8]. Once doctors restore blood flow (reperfusion), this stunned, viable muscle may recover and start pumping normally again [8][10].
Because of this natural healing process, your ejection fraction can improve over the weeks and months following your heart attack [11][12]. However, recovery is variable and not guaranteed; it depends on the size of the heart attack, how quickly blood flow was restored, and other individual factors. Treatment supports recovery and helps prevent harmful structural changes, but it cannot reverse established scar tissue.
ICDs and Long-Term Decisions: Because EF can improve, doctors generally wait to see how your heart responds to time and medication before making major long-term decisions. For example, if your EF remains very low, you might be evaluated for an implantable cardioverter-defibrillator (ICD) to protect against sudden dangerous heart rhythms [13]. For primary prevention (protecting you before any dangerous rhythm occurs), this decision is generally not made during the first 40 days after a heart attack, and often requires reassessment after about 90 days of optimized medical therapy or revascularization [13]. However, if you have already had certain dangerous arrhythmias, the timing and criteria may be different.
Medications for Reduced LVEF and Heart Failure
If your LVEF is reduced, your care team will likely prescribe specific medications to reduce the physical workload on your heart, prevent it from abnormally changing shape (remodeling), and support healing [14].
Important Note: The medications listed below are specifically for reduced EF and heart failure. They are only one part of your post-heart-attack care. Most patients will also need routine secondary-prevention medicines, such as antiplatelet drugs (like aspirin and another blood thinner if you have a stent) and a high-intensity statin to lower cholesterol. Do not start, stop, or change any medications without your care team’s direction.
Medications targeted at improving heart function and outcomes include:
- Beta-blockers: These medications slow your heart rate and lower your blood pressure, giving the heart more time to fill with blood and rest between beats. They require your doctor to monitor your heart rate and blood pressure [6].
- ACE inhibitors or ARBs: These drugs relax your blood vessels, making it easier for the heart to pump. They require individualized monitoring of your blood pressure and kidney function [14][6].
- Mineralocorticoid-receptor antagonists (MRAs): Medications like eplerenone are used in selected patients—typically those with an LVEF of 40% or lower plus heart failure symptoms or diabetes [15]. They require careful blood tests to monitor kidney function and potassium levels, as they can cause dangerous potassium buildup (hyperkalemia) [16].
- SGLT2 inhibitors: Originally used for diabetes, these medications have been shown to significantly reduce the risk of heart-failure hospitalizations and other cardiac events in eligible patients, regardless of whether they have diabetes [6][17]. They are not automatically prescribed to every post-MI patient, and their use requires reviewing your kidney function and fluid status [6].
The Number is Not the Whole Story
While LVEF is a vital clinical marker, it must always be interpreted alongside your physical symptoms and other test results [18]. A patient with an EF of 35% might feel energetic and have no physical limitations, while someone with an EF of 55% might struggle with severe shortness of breath. (Heart failure with preserved ejection fraction, or HFpEF, is a clinical syndrome diagnosed not just by fluid buildup, but by specific symptoms combined with evidence of elevated pressure inside the heart or other structural changes) [4][19].
Your doctor will look at your LVEF in combination with physical signs of fluid buildup (congestion), blood tests measuring heart stress (like natriuretic peptides), and your daily symptoms to get a complete, accurate picture of your recovery [19][18][20]. Never let a single percentage define how you feel or what you can achieve; always report your actual symptoms and physical capabilities to your medical team.
Common questions in this guide
What does an LVEF result tell me after a heart attack?
What is considered a normal or low ejection fraction after a heart attack?
Can my ejection fraction get better after a heart attack?
What treatments may be used when LVEF is reduced after a heart attack?
How long do doctors wait before considering an ICD for a low EF?
Which symptoms after a heart attack mean I need emergency help?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on acute myocardial infarction.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What was my exact ejection fraction, and when is my next echocardiogram scheduled to reassess it?
- 2.Did my echocardiogram show specific regional wall-motion abnormalities, and do they match the location of my heart attack?
- 3.Based on my current LVEF and symptoms, am I on the right combination of medications to protect my heart function, and do I need regular blood tests for my kidney function or potassium?
- 4.Given my current heart function, what is a safe timeline for me to return to work, driving, and normal physical activity, and am I a candidate for cardiac rehabilitation?
- 5.If my ejection fraction is currently low, what are the specific criteria and timeline for deciding if I need an implantable device (ICD)?
References
References (20)
- 1
Two-year clinical outcome of patients with mildly reduced ejection fraction after acute myocardial infarction: insights from the prospective KAMIR-NIH Registry.
Jeon HS, Lee JW, Moon JS, et al.
Frontiers in cardiovascular medicine 2024; (11()):1458740 doi:10.3389/fcvm.2024.1458740.
PMID: 39371398 - 2
Role of Lactate Dehydrogenase as a Biomarker of Early Cardiac Remodeling: A Cross-Sectional Study.
Brigic L, Mušija E, Kadić F, et al.
Cureus 2024; (16(9)):e68906 doi:10.7759/cureus.68906.
PMID: 39381455 - 3
Composite Echocardiographic Score to Predict Long-Term Survival Following Myocardial Infarction.
Krishnan A, Prasad SB, Guppy-Coles KB, et al.
Heart, lung & circulation 2022; (31(6)):795-803 doi:10.1016/j.hlc.2022.01.005.
PMID: 35221203 - 4
Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction.
Antonelli L, Katz M, Bacal F, et al.
Arquivos brasileiros de cardiologia 2015; (105(2)):145-50.
PMID: 26039659 - 5
Long-Term Risk of Cardiovascular Death in Patients With Mildly Reduced Ejection Fraction After Acute Myocardial Infarction: A Multicenter, Prospective Registry Study.
Kim H, Lee KY, Choo EH, et al.
Journal of the American Heart Association 2024; (13(18)):e034870 doi:10.1161/JAHA.124.034870.
PMID: 39248255 - 6
Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects.
Abel AAI, Clark AL
International journal of general medicine 2021; (14()):7797-7805 doi:10.2147/IJGM.S294896.
PMID: 34795500 - 7
Utilization of Intraoperative Real-time Three-Dimensional Transoesophageal Echocardiography to Objectively Assess Improvement in Synchronization and Regional Wall Motion after Coronary Reperfusion.
Karnwal A, Kakazu CZ, Shah S, et al.
Journal of clinical and diagnostic research : JCDR 2017; (11(3)):TD01-TD02 doi:10.7860/JCDR/2017/23592.9386.
PMID: 28473968 - 8
PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake.
Rischpler C, Langwieser N, Souvatzoglou M, et al.
European heart journal. Cardiovascular Imaging 2015; (16(6)):661-9 doi:10.1093/ehjci/jeu317.
PMID: 25680385 - 9
Peak CK-MB has a strong association with chronic scar size and wall motion abnormalities after revascularized non-transmural myocardial infarction - a prospective CMR study.
Pöyhönen P, Kylmälä M, Vesterinen P, et al.
BMC cardiovascular disorders 2018; (18(1)):27 doi:10.1186/s12872-018-0767-7.
PMID: 29422025 - 10
Impact of Total Ischemic Time on the Recovery of Regional Wall Motion Abnormality after STEMI in the Modern Reperfusion Era.
Seo JH, Kim KH, Chun KJ, et al.
Journal of interventional cardiology 2022; (2022()):2447707 doi:10.1155/2022/2447707.
PMID: 35136385 - 11
Effect of Guideline-Based Therapy on Left Ventricular Systolic Function Recovery After ST-Segment Elevation Myocardial Infarction.
Abou R, Leung M, Goedemans L, et al.
The American journal of cardiology 2018; (122(10)):1591-1597 doi:10.1016/j.amjcard.2018.07.035.
PMID: 30213383 - 12
Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome.
Chew DS, Heikki H, Schmidt G, et al.
JACC. Clinical electrophysiology 2018; (4(5)):672-682 doi:10.1016/j.jacep.2017.12.015.
PMID: 29798797 - 13
Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study.
Echivard M, Sellal JM, Ziliox C, et al.
European heart journal 2024; (45(41)):4428-4442 doi:10.1093/eurheartj/ehae575.
PMID: 39299922 - 14
Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Raposeiras-Roubín S, Abu-Assi E, Cespón-Fernández M, et al.
Revista espanola de cardiologia (English ed.) 2020; (73(2)):114-122 doi:10.1016/j.rec.2019.02.012.
PMID: 31105064 - 15
Role of eplerenone in the threatment of cardiovascular diseases.
Málek F
Vnitrni lekarstvi 2023; (69(E-2)):23-25 doi:10.36290/vnl.2023.025.
PMID: 37072263 - 16
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018.
Atherton JJ, Sindone A, De Pasquale CG, et al.
The Medical journal of Australia 2018; (209(8)):363-369 doi:10.5694/mja18.00647.
PMID: 30067937 - 17
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
Hernandez AF, Udell JA, Jones WS, et al.
Circulation 2024; (149(21)):1627-1638 doi:10.1161/CIRCULATIONAHA.124.069217.
PMID: 38581389 - 18
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
Udell JA, Petrie MC, Jones WS, et al.
Journal of the American College of Cardiology 2024; (83(23)):2233-2246 doi:10.1016/j.jacc.2024.03.405.
PMID: 38588929 - 19
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.
Bozkurt B, Coats AJS, Tsutsui H, et al.
European journal of heart failure 2021; (23(3)):352-380 doi:10.1002/ejhf.2115.
PMID: 33605000 - 20
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial.
Jering KS, Claggett BL, Braunwald E, et al.
Journal of cardiac failure 2026; (32(3)):586-595 doi:10.1016/j.cardfail.2025.03.018.
PMID: 40250826
This page is for informational purposes only and does not constitute medical advice. Your cardiology team should interpret your LVEF, symptoms, medications, and need for follow-up based on your individual situation.